Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary report. - Kawamura, Yusuke; Akuta, Norio; Shindoh, Junichi; Matsumura, Masaru; Okubo, Satoshi; Tominaga, Licht; Yamamoto, Shigeki; Eriksson, Yasuka; Hosaka, Tetsuya; Saitoh, Satoshi; Sezaki, Hitomi; Suzuki, Fumitaka; et al. (Hepatology Research, 2025)